

Joop van Gerven

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3087044/publications.pdf>

Version: 2024-02-01

13
papers

413
citations

932766

10
h-index

1125271

13
g-index

13
all docs

13
docs citations

13
times ranked

559
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2814-2829.	1.1	7
2	The impact of the global COVID-19 pandemic on the conduct of clinical trials: Return to normalcy by considering the practical impact of a structured ethical analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 837-844.	1.1	12
3	Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. <i>Journal of Psychopharmacology</i> , 2020, 34, 326-335.	2.0	22
4	Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. <i>European Neuropsychopharmacology</i> , 2019, 29, 847-857.	0.3	39
5	Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry. <i>Current Drug Metabolism</i> , 2019, 20, 254-265.	0.7	20
6	Commentary on the <sc>EMA Guideline</sc> on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1401-1409.	1.1	86
7	Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1022-1029.	2.3	52
8	Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 888-899.	1.1	10
9	Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1457-1466.	1.1	16
10	A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. <i>Journal of Psychopharmacology</i> , 2018, 32, 668-677.	2.0	44
11	How to define reference intervals to rule in healthy individuals for clinical trials?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, e59-e61.	1.4	3
12	The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 489-503.	1.3	56
13	Ketamine interactions with biomarkers of stress: A randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men. <i>NeuroImage</i> , 2015, 108, 396-409.	2.1	46